Another third generation ALK inhibitor lorlatinib is still in the phase 3 CROWN study, which can improve PFS (median duration of follow-up for PFS, 36.7 months), ORR (76 ~ 82%), duration of response (≥ 2 years, 74%), and time to intracranial progression (≥ 2 years, 81%) of advanced NSCLC patients [157]. Here, ALK is linked to non-small cell lung carcinoma.